Neoplasms

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Rare Diseases

Carcinoma

Adenocarcinoma

Carcinoma, Renal Cell

Kidney Neoplasms

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Kidney Diseases

Urologic Diseases

Male Urogenital Diseases

Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

Antineoplastic Agents

All Drugs and Chemicals

Nivolumab

Ipilimumab

Participants diagnosed with advanced renal cell carcinoma (RCC) and whose physician has decided to initiate a treatment with Nivolumab for the first time for the treatment of RCC

Participants diagnosed with advanced RCC and whose physician has decided to start a new systemic therapy with nivolumab + ipilimumab for the first time for the treatment of RCC

Bristol-Myers Squibb

This is a French, nationwide, prospective, observational, multi-center study in participants diagnosed with advanced renal cell carcinoma, who start a new systemic therapy with nivolumab with or without ipilimumab for the first time and within the market authorization approval.

Non-Interventional Study (NIS) of Nivolumab With or Without Ipilimumab in Participants With Advanced Kidney Cancer

A National, Prospective, Non-Interventional Study (NIS) of Nivolumab (BMS-936558) With or Without Ipilimumab (BMS-734016) in Patients With Advanced Renal Cell Carcinoma in Real Life Setting

The FKSI-19 will be graded by the patient on a scale from 0 to 4 (range "not at all to very much")

The EQ-5D descriptive system consists of 5 dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression, each with 3 levels (eg, no problems, moderate problems, extreme problems)

N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide

Carbonic Anhydrase Inhibitors

Enzyme Inhibitors

E7070

Murray Yule, MRCP, PhD

The purpose of this study is to determine if E7070 is a safe and effective treatment for cancer of the kidneys.

Renal Cell Carcinoma (RCC) accounts for approximately 2% of all cancers and its incidence is increasing with worldwide deaths of over 100,000 patients per year. About 50% of RCC patients have inoperable or metastatic disease that surgery cannot be performed on. RCC is also considered to be resistant to both radiotherapy and cytotoxic chemotherapy. The purpose of this study is to evaluate the safety and effectiveness of E7070 by assessing progression free survival, tumor response rate, duration of response/stable disease, and survival time. E7070 will be administered as a single iv infusion over 60 minutes on Day 1 of each cycle. Patients will continue treatment with E7070 until they no longer have clinical benefit and have disease progression, or toxicity leads to patient withdrawal.

A Safety, Tolerability and Efficacy Study of E7070 in Patients With Renal Cell Carcinoma

A Phase II Study of E7070 in Patients With Progressive Inoperable and/or Metastatic Renal Cell Carcinoma (RCC)

Eisai Inc.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Non-Interventional Study (NIS) of Nivolumab With or Without Ipilimumab in Participants With Advanced Kidney Cancer	NCT03455452	Renal Cell Carc... Renal Cell Canc... Adenocarcinoma ... Adenocarcinoma,... Kidney Cancer Cancer of the K...		18 Years -	Bristol-Myers Squibb
A Safety, Tolerability and Efficacy Study of E7070 in Patients With Renal Cell Carcinoma	NCT00059735	Kidney Neoplasm... Carcinoma, Rena... Adenocarcinoma,...	E7070	18 Years -	Eisai Inc.
A Safety, Tolerability and Efficacy Study of E7070 in Patients With Renal Cell Carcinoma	NCT00059735	Kidney Neoplasm... Carcinoma, Rena... Adenocarcinoma,...	E7070	18 Years -	Eisai Inc.

Spots Global Cancer Trial Database for adenocarcinoma, renal cell